Gene Therapy Market Size, Share, Latest Trends and Forecast 2026-2034

According to IMARC Group, the global gene therapy market size reached USD 6.6 Billion in 2025 and is projected to reach USD 19.3 Billion by 2034, expanding at a CAGR of 12.27% during 2026–2034. This robust gene therapy market growth trajectory reflects the rising global burden of genetic disorders, expanding regulatory support for advanced therapies, and sustained investment from biopharmaceutical and biotechnology companies in gene-based treatment platforms.

Gene Therapy Industry Overview

Gene therapy is a medical technique that modifies or manipulates genes within a patient’s cells to treat or prevent disease. Using viral or non-viral vectors to deliver therapeutic genetic material into target cells, gene therapy aims to replace faulty genes, introduce new genes, or deactivate problematic ones — offering potentially curative solutions for conditions that previously had limited treatment options.

Gene therapy applications span a wide range of use cases:

• Oncological disorders: CAR-T cell therapies, oncolytic viruses, and tumor suppressor gene delivery for hematological and solid tumors
• Rare and inherited diseases: Treatments for hemophilia, spinal muscular atrophy, muscular dystrophy, and metabolic disorders
• Cardiovascular disease: Gene-based approaches targeting underlying genetic risk factors
• Neurological disorders: Vector-delivered therapies addressing inaccessible or hard-to-treat conditions
• Infectious disease: Emerging genetic approaches to disease prevention and management

Global Gene Therapy Market Size & Key Statistics

Below are the key Gene Therapy Market statistics drawn from IMARC Group’s comprehensive market analysis:

Key Market Drivers & Gene Therapy Market Trends in 2026

Several powerful forces are shaping gene therapy market trends and fuelling sustained growth expectations across the global biopharmaceutical landscape:

1. Advancements in Viral Vector Technology

Continuous progress in viral vector technology remains a central growth driver. Therapeutic genes are delivered into patient cells through viral vectors, with adeno-associated viruses (AAVs) and lentiviruses gaining widespread application due to their ability to carry genetic material with minimal immune reaction. Researchers are also developing vectors capable of carrying larger genetic payloads, expanding the scope of treatable disorders while improving safety and efficacy.

2. Investment and Funding in Research and Development

Growing investment and funding for gene therapy R&D is a key pillar supporting market expansion. Pharmaceutical companies, biotechnology firms, and government agencies are committing substantial resources toward developing gene therapy platforms, with dedicated innovation funds supporting academic researchers advancing new therapies toward clinical readiness.

3. Rising Prevalence of Genetic Disorders and Rare Diseases

The increasing incidence of genetic disorders and rare diseases — many with limited existing treatment options — is propelling demand for gene-based therapies. As diagnostic capabilities and genetic understanding advance, more patients are being identified as candidates for gene therapy, reinforcing long-term Gene Therapy Market Growth across developed and emerging healthcare systems.

4. Regulatory Support and Accelerated Approval Pathways

Regulatory agencies worldwide are backing gene therapy through simplified approval procedures and incentive programs. Accelerated pathways for rare disease and oncology indications are boosting market confidence and encouraging biopharmaceutical companies to expand their gene therapy pipelines.

Key Market Segmentation

By Gene Type

Antigen — Largest Segment: Antigens are central to advancing immunotherapy, particularly in oncology, by enhancing the immune system’s ability to identify and eliminate cancer cells. These molecules underpin cancer vaccines and chimeric antigen receptor (CAR)-T cell therapies, with ongoing research focused on discovering novel antigens and refining delivery systems.

Other Gene Types: Cytokine, Tumor Suppressor, Suicide Gene, Deficiency, Growth Factors, Receptors, and Others round out the segment, each supporting specific therapeutic applications across oncology and rare disease treatment.

By Vector Type

Viral Vector — Largest Segment (55.5% share in 2025): Viral vectors — including adenoviruses, lentiviruses, retroviruses, adeno-associated virus, herpes simplex virus, poxvirus, and vaccinia virus — dominate due to superior efficiency in delivering genetic material into host cells. AAV has gained particular traction for its favorable safety profile, while lentiviruses and retroviruses are widely used in ex vivo therapies such as CAR-T treatments.

Non-Viral Techniques: Naked and plasmid vectors, gene gun, electroporation, lipofection, and other non-viral approaches represent an emerging alternative delivery pathway.

By Delivery Method

In-Vivo Gene Therapy — Largest Segment (71.5% share in 2025): In-vivo gene therapy delivers genetic material directly into a patient’s body using viral or non-viral vectors, making it particularly useful for treating diseases where affected cells are not easily accessible, including neurological disorders and liver diseases.

Ex-Vivo Gene Therapy: Involves modifying patient cells outside the body before reintroducing them, commonly used in CAR-T cell and other cell-based therapeutic approaches.

By Application

Oncological Disorders — Largest Application: Gene therapies targeting cancer are directed at altering genes to enhance immune response, inhibit tumor growth, or improve the effectiveness of existing therapies. CAR-T cell therapy, oncolytic viruses, and tumor suppressor gene delivery have shown strong results across hematological malignancies and solid tumors.

Other Applications: Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Others represent significant and growing application areas within the gene therapy pipeline.

Regional Gene Therapy Market Analysis

North America dominates the global Gene Therapy Market Size, holding over 56% share in 2025, underpinned by robust healthcare infrastructure, rising investments in research operations, advanced regulatory frameworks, and the presence of leading biotechnology firms.

Leading Players in the Global Gene Therapy Industry

The global gene therapy market features a mix of established biopharmaceutical multinationals and focused gene- and cell-therapy specialists. Key companies covered in the IMARC Group report include:

• Abeona Therapeutics Inc.
• Adverum Biotechnologies, Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• BioMarin Pharmaceutical Inc.
• bluebird bio, Inc.
• Gilead Sciences, Inc.
• Mustang Bio
• Novartis AG
• Orchard Therapeutics plc
• Roche Holding AG
• Sangamo Therapeutics
• uniQure NV

Latest Gene Therapy Market Industry Developments

October 2024 — Roche & Dyno Therapeutics

Roche announced plans to apply Dyno Therapeutics’ engineered adeno-associated virus (AAV) capsid platform to develop next-generation AAV vectors for gene therapies targeting neurological diseases, through a collaboration that could generate more than USD 1 billion for Dyno.

January 2024 — Ginkgo Bioworks & Biogen

Ginkgo Bioworks announced the successful completion of its gene therapy collaboration with Biogen, originally announced in May 2021, reinforcing continued momentum in gene therapy platform development partnerships.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Healthcare, Technology, Chemicals, Energy, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104

Article source: https://article-realm.com/article/Health-Fitness/85146-Gene-Therapy-Market-Size-Share-Latest-Trends-and-Forecast-2026-2034.html